Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

  • Technology appraisal guidance
  • TA492
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 739.